KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Free Cash Flow for 6 consecutive years, with -$47.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 59.46% year-over-year to -$47.3 million, compared with a TTM value of -$378.3 million through Dec 2025, down 1.45%, and an annual FY2025 reading of -$378.3 million, down 1.45% over the prior year.
  • Free Cash Flow was -$47.3 million for Q4 2025 at Recursion Pharmaceuticals, up from -$117.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $73.0 million in Q1 2022 and bottomed at -$133.8 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$66.2 million, with a median of -$66.9 million recorded in 2023.
  • The sharpest move saw Free Cash Flow tumbled 2457.11% in 2021, then surged 245.59% in 2022.
  • Year by year, Free Cash Flow stood at -$65.6 million in 2021, then skyrocketed by 75.22% to -$16.3 million in 2022, then tumbled by 309.79% to -$66.6 million in 2023, then crashed by 75.19% to -$116.7 million in 2024, then surged by 59.46% to -$47.3 million in 2025.
  • Business Quant data shows Free Cash Flow for RXRX at -$47.3 million in Q4 2025, -$117.6 million in Q3 2025, and -$79.6 million in Q2 2025.